Welcome to Mission: Cure’s collection of resources on pancreatitis treatment options. Here, you’ll find articles covering various approaches—from medical therapies to lifestyle adjustments and emerging treatments—designed to help manage symptoms and enhance quality of life for those affected by pancreatitis. Explore the latest insights and updates to stay informed on ways to improve care and support.
At a recent Mission: Cure patient education webinar, Joshua Henderson, our Chief Cure Strategy Officer, walked attendees through the current landscape of pancreatitis research: how new treatments move from an idea to FDA approval, the difference between clinical trials and observational studies, and the trials patients can join today. The conversation sparked so many great
Pancreatitis Research Webinar: Community FAQ Read More »
We have some exciting news for people living with pancreatitis caused by the FCS genetic mutation. On November 18, 2025, the FDA has approved REDEMPLO® (plozasiran), a new treatment from Arrowhead Pharmaceuticals that lowers triglycerides and reduces acute pancreatitis attacks in adults with Familial Chylomicronemia Syndrome (FCS). This is an important step for people with
FDA Approves New Treatment for Familial Chylomicronemia Syndrome (FCS) Read More »
High triglycerides are one of the leading causes of pancreatitis, and for some people, extremely high levels can be caused by a rare genetic condition called Familial Chylomicronemia Syndrome (FCS). We’re excited to share a new resource created for and by the FCS community in partnership with Arrowhead Pharmaceuticals. This was specifically designed for people
New Resource: Managing Life with FCS – A Peer Support Toolbox Read More »
For people living with IgG4-Related Disease (IgG4-RD), treatment can be complicated. The disease is rare, often misdiagnosed, and can affect many different organs. When it affects the pancreas, it is called Type 1 Autoimmune Pancreatitis (AIP). Steroids are usually the first treatment doctors prescribe because they quickly reduce inflammation, improve symptoms, and induce remission, and
The Risks of Steroid Use for Type 1 Autoimmune Pancreatitis (IgG4-RD) Read More »
On April 3, 2025, the FDA approved Uplizna® (inebilizumab-cdon) as the first and only approved treatment for Immunoglobulin G4-related disease (IgG4-RD), the condition behind Type 1 Autoimmune Pancreatitis (AIP). This is a huge milestone. It’s the first time a treatment has been officially approved for this rare, immune-related cause of pancreatitis. For patients living with
Exciting news! On December 19, 2024, the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA (olezarsen), developed by Ionis, as the first-ever treatment for Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic condition that causes dangerously high triglyceride levels, increasing the risk of severe health complications–especially pancreatitis. This approval is a major milestone—not
FDA Approves First-Ever Treatment for Familial Chylomicronemia Syndrome (FCS) Read More »
In this Mission: Cure patient education webinar, medical experts discuss current clinical trials available to pancreatitis patients. A clinical trial is a research study to test new treatments on people. It is a critical step in the process of getting a new treatment approved so that it can be given to patients. After a treatment,
New Pancreatitis Therapies: Current Clinical Trials Read More »
Acute pancreatitis, a life-threatening condition, occurs suddenly and is often idiopathic (meaning, for unknown reasons). Although treatment specific to the disease is lacking, it usually resolves with proper clinical management. Multiple episodes may occur over time, leading to recurrent acute pancreatitis, which can eventually lead to chronic pancreatitis. Chronic pancreatitis is irreversible inflammatory and fibrotic
When will we have new treatments for pancreatitis? In July, Mission: Cure met with researchers and doctors to discuss this important question. Mission: Cure CEO Megan Golden, VP for Translational Research Lola Rahib, and the summer interns attended PancreasFest 2022 at the University of Pittsburgh. PancreasFest is an annual conference that brings together researchers who
Getting Ready to Test New Pancreatitis Treatments: News from PancreasFest Read More »
Mission: Cure has provided initial funding to Johns Hopkins Medicine to launch the new Pancreatitis Pain Research Center. Mission: Cure will work with Johns Hopkins to establish the Pancreatitis Pain Research Program. The goals for the pancreatitis pain program are: To study and treat specific types of pain associated with chronic pancreatitis To create an
New Collaboration with Johns Hopkins to Treat Pancreatitis Pain Read More »
Before You Go
Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care.
